Kennedy, a well-known vaccine skeptic, last week announced plans to reshape federal public health agencies, including cutting ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Key Takeaways The U.S. Food and Drug Administration has delayed full approval of Novavax's COVID vaccineThe agency says it needs more data before making a final decisionNovavax says its vaccine is ...

More top vaccine regulators at the FDA have either left or been forced out, which could hobble the agency's ability to ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Ex-vaccine regulator Peter Marks promoted "ineffective therapy that gave patients false hope, eroded trust in the regulatory ...

Novavax's COVID-19 vaccine received FDA Emergency Use Authorization, but full approval faces delays as regulators request more data beyond the April 1 deadline.

Amid a raft of federal changes cutting funding and capacities at the Food and Drug Administration, investors are soon ...

The live vaccine is produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

President Trump yesterday announced a baseline tariff of 10% on all imported products and higher rates on certain countries ...